Breaking News

Financial Report: AbbVie

By Kristin Brooks | January 31, 2014

Revenues down 2% in the quarter

4Q Revenues: $5.1 billion (-2%)
4Q Earnings:
$1.1 billion (-27%)
FY Revenues: $18.8 billion (+2%)
FY Earnings: $4.1 billion (-22%)
Comments: Global Humira sales increased 13% to $3.0 billion in the quarter. U.S. Humira sales grew 18% to $1.7 billion. Synagis sales were $314 million, down 6%. AndroGel sales were down 21% to $289 million. Kaletra sales were $228 million, down 9%. Lupron sales were $209 million, down 1%. Synthroid sales were up 13% to $189 million. Niaspan and TriCor/Trilipix sales were down 89% and 85% respectively, due to generic competition. R&D expenses were up 17% to $798 million in the quarter.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus